RFCA
TTPH

R&F Capital Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

R&F Capital Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,189
Closed -$96K – 874
2016
Q4 		$96K Buy
+1,189
New +$94.1K 0.03% 451

Other funds holding TTPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

R&F Capital Advisors's TTPH Position: Q1 2017 in Review

R&F Capital Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2017, closing a stake of 1,189 shares — an estimated $96K sold.

R&F Capital Advisors first reported a position in TTPH in Q4 2016 and held it in 1 quarter. The position peaked at $96K in Q4 2016. 89 funds tracked by Wall St. Rank hold TTPH as of Q1 2017.

  • R&F Capital Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 1,189 Tetraphase Pharmaceuticals, Inc. shares in Q1 2017, an estimated $96K.
  • R&F Capital Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $96K in Q4 2016.
  • 89 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.